WINDSOR, CONN. (Jan. 28, 2021)– SCA Pharmaceuticals, LLC, announced details last week of their acquisition by The Vistria Group and Excellere. Continuing their strategic growth initiatives, SCA Pharma is announcing the appointment of Mr. Scott Luce as Chief Commercial Officer. Mr. Luce will provide leadership and oversight of commercial operations as SCA Pharma continues to develop and execute its growth initiatives.
Mr. Luce brings over 30 years of leadership experience in accelerating global sales and profit growth in pharmaceuticals, biologics, and medical devices by driving focus on innovation and customer experience. Notably, Mr. Luce has significant experience in bringing products and services to the hospital sector.
Most recently, Mr. Luce has been working with The Vistria Group as an Operating Partner where he has helped develop and execute Vistria’s healthcare sector investment strategy. Prior to The Vistria Group, Mr. Luce held numerous positions in General Management, Sales and Marketing, and Business Development with both Abbott and Baxter.
“We are very excited to add this strategic role to our leadership team,” said Milton Boyer, CEO of SCA Pharma. “Mr. Luce’s vast experience in leadership, operational performance and Specialty Pharmaceuticals will allow SCA Pharma to focus on meeting market demands for both the products and services we provide to hospital pharmacies.”
“I am very excited to join the SCA Pharma team,” stated Mr. Luce. “The mission and critical role that SCA Pharma has played by providing hospitals with a reliable source of safe, ready-to-use product with its customers has never been more significant than it is in today’s marketplace. We will continue to be customer centric in our delivery of both products and services.”
Mr. Luce earned a Bachelor of Science degree in Marketing from Indiana University and a Master of Business Administration from Lake Forest Graduate School of Management.
